Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
A three-tier system for classifying the scientific evidence behind peptides
At 13:25 · chapter starts 10:00
Building on the five-question framework, Peter introduces a three-bucket classification system for peptides based on the quality and type of available evidence. Bucket 1 is the scientifically unsupported tier: no validated mechanism, no credible human evidence, and claims that tend to drift over time without clinical progress to justify them. Bucket 2 has biologically plausible compounds — the mechanism is credible and animal data may exist — but no demonstrated human benefit; development has often stalled or halted because the compound wasn't effective enough, wasn't safe enough, or was beaten by a better drug. Bucket 3 contains the scientifically legitimate molecules, but Peter immediately flags a critical nuance: evidence is not a property of a molecule — it belongs to a specific clinical question defined by dose, route of administration, patient population, indication, and endpoint. [1] — Peter Attia "Not all peptides are equal. Tier 1 has no validated mechanism and no credible human data. Tier 2 has plausible biology but no proven human …" 10:17 Being in Bucket 3 is not an endorsement; it means the molecule has the strongest scientific footing, not that any given gray-market use of it is justified.
Not all peptides are equal. Tier 1 has no validated mechanism and no credible human data. Tier 2 has plausible biology but no proven human outcomes. Tier 3 has legitimate scientific footing — but even here, evidence is tied to a specific dose, route, population, and indication, not the molecule itself.
